# A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

> **NCT02082899** · PHASE2 · COMPLETED · sponsor: **Eleven Biotherapeutics** · enrollment: 150 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Active Comparator EBI-005 5 mg/mL
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT02082899
- **Lead sponsor:** Eleven Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-06
- **Final completion:** 2014-07
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2014-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02082899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02082899, "A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02082899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*